128 related articles for article (PubMed ID: 37398262)
21. National introduction of human papillomavirus (HPV) vaccine in Tanzania: Programmatic decision-making and implementation.
Mphuru A; Li AJ; Kyesi F; Mwengee W; Mazige F; Nshunju R; Shayo B; Giattas MR; Loharikar A; Lyimo D
Vaccine; 2022 Mar; 40 Suppl 1(Suppl 1):A2-A9. PubMed ID: 33962839
[TBL] [Abstract][Full Text] [Related]
22. Improving skills and institutional capacity to strengthen adolescent immunisation programmes and health systems in African countries through HPV vaccine introduction.
Dochez C; Burnett RJ; Mbassi SM; Were F; Musyoki A; Trovoada D; Mphahlele MJ
Papillomavirus Res; 2017 Dec; 4():66-71. PubMed ID: 29179872
[TBL] [Abstract][Full Text] [Related]
23. Global impact and cost-effectiveness of one-dose versus two-dose human papillomavirus vaccination schedules: a comparative modelling analysis.
Prem K; Choi YH; Bénard É; Burger EA; Hadley L; Laprise JF; Regan MC; Drolet M; Sy S; Abbas K; Portnoy A; Kim JJ; Brisson M; Jit M
BMC Med; 2023 Aug; 21(1):313. PubMed ID: 37635227
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness and equity impacts of three HPV vaccination programmes for school-aged girls in New Zealand.
Blakely T; Kvizhinadze G; Karvonen T; Pearson AL; Smith M; Wilson N
Vaccine; 2014 May; 32(22):2645-56. PubMed ID: 24662710
[TBL] [Abstract][Full Text] [Related]
25. Impact, cost-effectiveness, and budget implications of HPV vaccination in Kenya: A modelling study.
Mwenda V; Jalang'o R; Miano C; Bor JP; Nyangasi M; Mecca L; Were V; Kariithi E; Pecenka C; Schuind A; Abbas K; Clark A
Vaccine; 2023 Jun; 41(29):4228-4238. PubMed ID: 37296015
[TBL] [Abstract][Full Text] [Related]
26. Costs of human papillomavirus vaccine delivery in low- and middle-income countries: A systematic review.
Slavkovsky R; Callen E; Pecenka C; Mvundura M
Vaccine; 2024 Feb; 42(6):1200-1210. PubMed ID: 38302338
[TBL] [Abstract][Full Text] [Related]
27. Health and economic benefits of single-dose HPV vaccination in a Gavi-eligible country.
Burger EA; Campos NG; Sy S; Regan C; Kim JJ
Vaccine; 2018 Aug; 36(32 Pt A):4823-4829. PubMed ID: 29807710
[TBL] [Abstract][Full Text] [Related]
28. Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: a mathematical modelling analysis.
Drolet M; Laprise JF; Martin D; Jit M; Bénard É; Gingras G; Boily MC; Alary M; Baussano I; Hutubessy R; Brisson M
Lancet Infect Dis; 2021 Nov; 21(11):1598-1610. PubMed ID: 34245682
[TBL] [Abstract][Full Text] [Related]
29. Challenges and lessons from a school-based human papillomavirus (HPV) vaccination program for adolescent girls in a rural Nigerian community.
Egbon M; Ojo T; Aliyu A; Bagudu ZS
BMC Public Health; 2022 Aug; 22(1):1611. PubMed ID: 36002832
[TBL] [Abstract][Full Text] [Related]
30. The cost of human papillomavirus vaccination delivery at the administrative and health facility levels in the Philippines.
Aldaba JG; Llave CL; Uy MEV; Tejano KP; Aquino MRC; Antonio P Catalig M; Sy ADR; Valverde HA; Mooney J; Slavkovsky R
Vaccine X; 2024 Mar; 17():100459. PubMed ID: 38420134
[TBL] [Abstract][Full Text] [Related]
31. Misinformation Drives Low Human Papillomavirus Vaccination Coverage in South African Girls Attending Private Schools.
Milondzo T; Meyer JC; Dochez C; Burnett RJ
Front Public Health; 2021; 9():598625. PubMed ID: 33681125
[No Abstract] [Full Text] [Related]
32. Resources Required for Cervical Cancer Prevention in Low- and Middle-Income Countries.
Campos NG; Sharma M; Clark A; Kim JJ; Resch SC
PLoS One; 2016; 11(10):e0164000. PubMed ID: 27711124
[TBL] [Abstract][Full Text] [Related]
33. Human papillomavirus (HPV) vaccination program in Sri Lanka: Ongoing costs and operational context of a routinized program.
Debellut F; Gamage D; Kumar S; Wickramasinghe S; Ruwanpathirana T; Kariyawasam M; Perera CS; Ginige S; Cooray N; Pecenka C; Slavkovsky R; Scott LaMontagne D; Mvundura M
Vaccine X; 2024 Mar; 17():100456. PubMed ID: 38379668
[TBL] [Abstract][Full Text] [Related]
34. Implementation strategy and cost of Mozambique's HPV vaccine demonstration project.
Soi C; Babigumira JB; Chilundo B; Muchanga V; Matsinhe L; Gimbel S; Augusto O; Sherr K
BMC Public Health; 2019 Oct; 19(1):1406. PubMed ID: 31664976
[TBL] [Abstract][Full Text] [Related]
35. Community-based household assessment of human papillomavirus (HPV) vaccination coverage and acceptability - HPV vaccine demonstration program, Cambodia - 2017.
Garon J; Wuddhika IV; Sreenivasan N; Wannemuehler K; Vutthikol Y; Chhorvann C; Loharikar A
Vaccine; 2019 Feb; 37(9):1202-1208. PubMed ID: 30686637
[TBL] [Abstract][Full Text] [Related]
36. Health and economic impact of human papillomavirus 16 and 18 vaccination of preadolescent girls and cervical cancer screening of adult women in Peru.
Goldie SJ; Levin C; Mosqueira-Lovón NR; Ortendahl J; Kim J; O'Shea M; Diaz Sanchez M; Mendoza Araujo MA
Rev Panam Salud Publica; 2012 Dec; 32(6):426-34. PubMed ID: 23370186
[TBL] [Abstract][Full Text] [Related]
37. A cost comparison of introducing and delivering pneumococcal, rotavirus and human papillomavirus vaccines in Rwanda.
Ngabo F; Levin A; Wang SA; Gatera M; Rugambwa C; Kayonga C; Donnen P; Lepage P; Hutubessy R
Vaccine; 2015 Dec; 33(51):7357-7363. PubMed ID: 26519548
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of the introduction of two-dose bi-valent (Cervarix) and quadrivalent (Gardasil) HPV vaccination for adolescent girls in Bangladesh.
Mahumud RA; Gow J; Alam K; Keramat SA; Hossain MG; Sultana M; Sarker AR; Islam SMS
Vaccine; 2020 Jan; 38(2):165-172. PubMed ID: 31668820
[TBL] [Abstract][Full Text] [Related]
39. Knowledge and willingness of parents towards child girl HPV vaccination in Debre Tabor Town, Ethiopia: a community-based cross-sectional study.
Mihretie GN; Liyeh TM; Ayele AD; Belay HG; Yimer TS; Miskr AD
Reprod Health; 2022 Jun; 19(1):136. PubMed ID: 35689288
[TBL] [Abstract][Full Text] [Related]
40. National introduction of HPV vaccination in Senegal-Successes, challenges, and lessons learned.
Casey RM; Adrien N; Badiane O; Diallo A; Loko Roka J; Brennan T; Doshi R; Garon J; Loharikar A
Vaccine; 2022 Mar; 40 Suppl 1(Suppl 1):A10-A16. PubMed ID: 34593269
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
